• Linezolid: Mechanism, Evidence, and Research Use

  2026-10-01

  Linezolid is a synthetic oxazolidinone antimicrobial that inhibits bacterial protein synthesis by disrupting formation of the 70S initiation complex. Its research relevance includes MRSA treatment research, vancomycin-resistant Enterococcus research, and bacterial pneumonia research, but assay endpoints and organism coverage must be interpreted separately.

• Ampicillin sodium in Antibacterial Research

  2026-09-30

  Ampicillin sodium supports mechanism-led antibacterial activity assays, resistance-aware strain profiling, and carefully designed bacterial infection model studies. This guide translates its transpeptidase inhibition into practical workflows, quantitative controls, and troubleshooting decisions that improve reproducibility.

• Magneto-Piezoelectric Scaffolds for Bone Repair

  2026-09-29

  Wu and colleagues developed a dual-responsive scaffold that combines biofilm disruption with targeted immunometabolic repair of infectious bone defects. The study links ultrasound-activated oxidative phosphorylation in Icam1+ macrophages to JAK2-STAT3 stimulation and MAPK-JNK suppression, providing a mechanistic framework for coordinating infection control and bone regeneration.

• Cefodizime Research Workflows for Resistance Studies

  2026-09-29

  Build reproducible Cefodizime assays around PBP-targeted bactericidal activity, isolate-level susceptibility testing, and resistance surveillance. This workflow connects quantitative MIC experiments with the hospital-use signals reported in a 2025 psychiatric hospital study while keeping clinical conclusions and laboratory evidence distinct.

• Antimycin A4: A Mechanism-Mapping Guide

  2026-09-28

  Antimycin A4 is both an ATP-citrate lyase inhibitor and a mitochondrial respiratory-chain probe, creating a powerful but easily confounded system for metabolic research. This guide explains how to separate direct enzyme inhibition from secondary energy failure and draws a practical assay-design lesson from asymmetric natural-product synthesis.

• Pertussis Toxin: Workflows & Troubleshooting

  2026-09-28

  Use Pertussis toxin to probe cAMP-linked immune responses and dendritic-cell function, with a practical pilot workflow that separates suggested starting conditions from established product specifications. The article also explains how to place toxin-based assays alongside TH17-lineage research without mistaking adjacent mechanisms for direct evidence.

• Olive Oil Polyphenols and Cardiovascular Protection

  2026-09-27

  Boumezough et al. compared phenolic extracts from standard and naturally high-phenolic extra virgin olive oil with hydroxytyrosol and tyrosol in cell-based assays of oxidative stress, macrophage inflammation, and cholesterol efflux. The findings connect phenolic concentration with measurable differences in selected antioxidant and cholesterol-efflux outcomes, while highlighting the need to test these mechanisms beyond in vitro models.

• Temafloxacin Activity Against Gram-Negative Bacteria

  2026-09-26

  Dwight J. Hardy’s 1991 overview compares temafloxacin’s in vitro activity with ciprofloxacin and ofloxacin across respiratory, enteric, and other gram-negative pathogens. Its central contribution is a pathogen-specific account of susceptibility: temafloxacin showed strong activity against many organisms, but was less active than ciprofloxacin against Pseudomonas aeruginosa.

• 740 Y-P as a PI3K Probe in Mitophagy Research

  2026-09-25

  Explore how 740 Y-P, a PI 3-kinase activator, can test pathway direction in mitophagy and chondrocyte-inflammation studies. This article connects recent gout-arthritis findings to practical assay design while clarifying what the evidence does—and does not—show.

• Topotecan (SKF104864): Cancer Research Workflows

  2026-09-25

  Build a practical Topotecan workflow that connects topoisomerase I inhibition to DNA-damage, cell-cycle, and apoptosis readouts. The guide also shows how to interpret those assays in glioma and pediatric tumor models without confusing preclinical findings with clinical evidence.

• Cinoxacin BA1045: Practical Gram-Negative Assays

  2026-09-24

  A scenario-driven guide to using Cinoxacin (SKU BA1045) in bacterial susceptibility and viability workflows, with practical limits for solvent handling, organism selection, and interpretation. It distinguishes supported product data from workflow recommendations and links assay design to published Cinoxacin evidence.

• Nicotine Signaling and CKD Progression in Smokers

  2026-09-24

  Jain and Jaimes review clinical and experimental evidence linking nicotine exposure with worsening chronic kidney disease (CKD), highlighting renal nicotinic acetylcholine receptors, reactive oxygen species, and pro-fibrotic signaling. The review frames nicotine as one contributor to smoking-associated renal injury while emphasizing that the mechanisms and their clinical relevance require further study.

• PD0325901: MEK Biology Beyond Pathway Shutdown

  2026-09-24

  PD0325901 offers translational researchers a defined way to perturb MEK and examine how RAS/RAF/MEK/ERK signaling shapes cancer-cell behavior. This article connects its reported effects on ERK phosphorylation, cell-cycle progression, apoptosis-associated readouts, and xenograft growth to a broader experimental principle: distinguish pathway-specific responses from parallel cellular stress signals. It also outlines practical controls, compound handling, and the limits of translating research-model results into clinical conclusions.

• Cefodizime and E. coli: Reading Resistance in Context

  2026-09-23

  Cefodizime is a third-generation cephalosporin antibiotic whose activity depends on both bacterial targets and resistance context. This article interprets cefodizime resistance reported in urban-rodent E. coli as a practical lesson in antimicrobial surveillance and assay design—not as a standalone prediction of treatment response.

• Fumagillin: MetAP-2 Inhibition and Angiogenesis

  2026-09-22

  Fumagillin is a methionine aminopeptidase-2 inhibitor used to study endothelial cell proliferation inhibition, angiogenesis, and tumor biology. Product data support antiangiogenic and tumor-growth research applications, while a peer-reviewed aquaculture study found moderate 24-hour in vitro activity against Azumiobodo hoyamushi.

8141 records 3/543 page Previous Next 12345 下5页 Last page